Optimapharm Company Profile

Background

Overview

Optimapharm is a leading, mid-sized, full-service Contract Research Organization (CRO) specializing in managing clinical trials for pharmaceutical, biotechnology, and medical device companies. Established in 2006 and headquartered in Zagreb, Croatia, the company operates across Europe and North America, offering comprehensive services in clinical development.

Mission and Vision

Optimapharm's mission is to deliver new therapies that improve and save patients' lives. The company envisions becoming a trusted partner in clinical research by providing high-quality, cost-effective solutions tailored to client needs.

Primary Area of Focus

The company focuses on conducting Phase I-IV clinical trials across various therapeutic areas, including oncology, neurosciences, cardiology, endocrinology, and infectious diseases. Optimapharm also has significant experience in medical device studies.

Industry Significance

As a full-service CRO, Optimapharm plays a crucial role in accelerating the development of new medical treatments by providing essential services that support the entire clinical trial process. Its extensive network and expertise enable efficient patient recruitment and high-quality data collection, contributing to the advancement of healthcare.

Key Strategic Focus

Core Objectives

Expansion of Geographic Presence: Optimapharm aims to broaden its operational footprint by establishing offices in key markets, including the United States and Hungary, to enhance client collaboration and access to diverse patient populations.

Service Diversification: The company seeks to expand its service offerings to include medical device studies and real-world evidence projects, catering to a broader range of client needs.

Specific Areas of Specialization

Oncology: Optimapharm has a strong focus on oncology, managing complex clinical trials in this therapeutic area.

Medical Device Studies: The company offers specialized services for medical device clinical trials, ensuring compliance with regulatory standards and efficient study execution.

Key Technologies Utilized

Data Management Systems: Optimapharm employs advanced data management platforms to ensure accurate and timely data collection and analysis.

Clinical Trial Management Software: The company utilizes comprehensive software solutions to streamline trial planning, monitoring, and reporting processes.

Primary Markets Targeted

Europe: With offices in 27 countries, Optimapharm has a significant presence across Europe, including Western, Central, and Eastern regions.

North America: The company has expanded into the U.S. market with offices in New York and Boston, aiming to strengthen its position in North America.

Financials and Funding

Funding History

Investment by The Rohatyn Group (TRG): In May 2020, TRG, along with Kartesia and Keyhaven Capital Partners, acquired Optimapharm from Accession Capital Partners, providing significant capital to support the company's growth and expansion strategies.

Total Funds Raised

Specific details regarding the total funds raised by Optimapharm are not publicly disclosed.

Notable Investors

The Rohatyn Group (TRG): An emerging markets-focused asset management firm that invested in Optimapharm in 2020.

Kartesia: A European private debt specialist that participated in the 2020 investment round.

Keyhaven Capital Partners: A private equity firm involved in the 2020 acquisition of Optimapharm.

Intended Utilization of Capital

The capital from these investments is intended to support Optimapharm's strategic growth initiatives, including geographic expansion, service diversification, and the enhancement of operational capabilities to better serve clients.

Pipeline Development

As a CRO, Optimapharm does not develop its own pharmaceutical products but instead manages clinical trials for its clients. The company's pipeline consists of various clinical studies across multiple therapeutic areas, including oncology, neurosciences, cardiology, endocrinology, and infectious diseases. Optimapharm's expertise in managing complex trials contributes to the successful development of new therapies by its clients.

Technological Platform and Innovation

Proprietary Technologies

Optimapharm utilizes proprietary data management and clinical trial management systems to ensure efficient and accurate execution of clinical studies.

Significant Scientific Methods

Patient Recruitment Strategies: The company employs innovative approaches to expedite patient recruitment, ensuring timely enrollment and retention in clinical trials.

Data Analytics: Optimapharm applies advanced data analytics to monitor trial progress, assess data quality, and provide actionable insights to clients.

Leadership Team

Executive Profiles

Ivana Waller – Chief Executive Officer (CEO): With over 25 years of experience in the pharmaceutical industry, Ivana has held various leadership positions in clinical research organizations. She joined Optimapharm in 2022, bringing a wealth of knowledge to drive the company's strategic initiatives.

Mirna Šenjug Novak – Chief Operating Officer (COO): Mirna has extensive experience in clinical operations and has been instrumental in optimizing Optimapharm's operational processes to enhance service delivery.

Miguel Angel Salcedo Iglesias – Chief Business Development Officer (CBDO): Miguel Angel leads the business development efforts, focusing on expanding Optimapharm's client base and exploring new market opportunities.

Leadership Changes

Appointment of Ivana Waller as CEO: In March 2022, Ivana Waller was appointed as the new CEO of Optimapharm, succeeding the previous CEO.

Competitor Profile

Market Insights and Dynamics

The global contract research organization (CRO) market is experiencing significant growth, driven by increased outsourcing of clinical trials by pharmaceutical and biotechnology companies. The U.S. CRO market alone is valued at approximately $20 billion, with expectations of continued growth due to rising investments in R&D and an increasing number of clinical research projects, particularly in oncology.

Competitor Analysis

Marti Farm: A CRO with a focus on clinical trial services, competing in similar therapeutic areas.

Veristat: A full-service CRO offering a range of clinical trial services, including regulatory affairs and clinical monitoring.

WCCT: Specializes in early-phase clinical trials, providing services from Phase I to proof-of-concept studies.

Strategic Collaborations and Partnerships

Optimapharm has formed strategic partnerships to enhance its service offerings and expand its market reach. Notably, the acquisition of Qualitis SA in 2022 strengthened its presence in Southern Europe, particularly in Greece.

Operational Insights

Optimapharm differentiates itself through its extensive network of over 1,000 active investigational sites, enabling efficient patient recruitment and high-quality data collection. The company's commitment to quality and client satisfaction is reflected in its 85% client retention rate.

Strategic Opportunities and Future Directions

Optimapharm continues to pursue growth through a combination of organic expansion and strategic acquisitions. The company's recent investments in the U.S. market and Southern Europe position it to capitalize on emerging opportunities and strengthen its global presence.